摘要
目的分析奥希替尼联合培美曲塞、顺铂对表皮生长因子受体(EGFR)突变阳性晚期非小细胞肺癌(NSCLC)的疗效。方法选取2020年2月至2022年2月南阳市中心医院收治的148例EGFR突变阳性晚期NSCLC患者,按随机数表法分为靶向治疗组与化疗组,各74例。化疗组接受培美曲塞、顺铂治疗,靶向治疗组接受奥希替尼联合培美曲塞、顺铂治疗。对比两组疾病控制率、T淋巴细胞亚群(CD4^(+)、CD8^(+))、血管生成指标[细胞质胸苷激酶(TK1)、血管内皮生长因子(VEGF)]、血清肿瘤标志物[癌胚抗原(CEA)、糖类抗原50(CA50)、糖类抗原125(CA125)]、卡氏功能状态评分(KPS)、不良反应发生率。结果靶向治疗组疾病控制率[60.81%(45/74)]较化疗组[44.59%(33/74)]高(P<0.05)。治疗后,靶向治疗组CD4^(+)较化疗组高,CD8^(+)较化疗组低(P<0.05)。治疗后,靶向治疗组TK1、VEGF较化疗组低(P<0.05)。治疗后,靶向治疗组血清CEA、CA50、CA125水平较化疗组低(P<0.05)。治疗后,靶向治疗组KPS评分较化疗组高(P<0.05)。两组不良反应发生率差异无统计学意义(P>0.05)。结论奥希替尼联合培美曲塞、顺铂治疗EGFR突变阳性晚期NSCLC,能改善免疫功能,抑制血管生成,降低肿瘤标志物水平,提高疾病控制率,改善机体功能状况,且安全性良好。
Objective To analyze the clinical effect of osimertinib combined with pemetrexed and cisplatin in the treatment of epidermal growth factor receptor(EGFR)mutation positive advanced non-small cell lung cancer(NSCLC).Methods A total of 148 patients with EGFR mutation positive advanced NSCLC in Nanyang Central Hospital from February 2020 to February 2022 were selected and randomly divided into targeted therapy group and chemotherapy group,with 74 cases in each group.The chemotherapy group was treated with pemetrexed and cisplatin,and the targeted therapy group was treated with osimertinib combined with pemetrexed and cisplatin.The disease control rate,T lymphocyte subsets(CD4^(+),CD8^(+)),angiogenesis indicators(TK1,VEGF),serum tumor markers(CEA,CA50,CA125),KPS score,and the incidence of adverse reactions were compared between the two groups.Results The disease control rate of the targeted therapy group was 60.81%(45/74),which was higher than that of the chemotherapy group(44.59%,33/74)(P<0.05).After treatment,CD4^(+)in the targeted therapy group was higher than that in the chemotherapy group,and CD8^(+)was lower than that in the chemotherapy group(P<0.05).After treatment,TK1 and VEGF in the targeted therapy group were lower than those in the chemotherapy group(P<0.05).After treatment,the levels of serum CEA,CA50 and CA125 in the targeted therapy group were lower than those in the chemotherapy group(P<0.05).After treatment,the KPS score of the targeted therapy group was higher than that of the chemotherapy group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Osimertinib combined with pemetrexed and cisplatin in the treatment of EGFR mutation positive advanced NSCLC can improve immune function,inhibit angiogenesis,reduce tumor markers,improve disease control rate,improve body function,and Good security.
作者
穆艳艳
张敬伟
袁小笋
徐赟
MU Yanyan;ZHANG Jingwei;YUAN Xiaosun;XU Yun(Department of Tumor Biological Immunotherapy,Nanyang Central Hospital,Nanyang 473000,China)
出处
《河南医学研究》
CAS
2024年第1期141-144,共4页
Henan Medical Research
关键词
非小细胞肺癌
表皮生长因子受体
突变
奥希替尼
培美曲塞
顺铂
non-small cell lung cancer
epidermal growth factor receptor
mutatior
osimertinib
pemetrexed
cisplatin
